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Key Words: vaccine, pregnancy, immunization As early as the 19th century vaccination in pregnancy has been observed to protect 
both mothers and infants against smallpox, per-
tussis and tetanus. More recently the pace and 
focus of maternal vaccination has accelerated, 
most significantly since the influenza pandemic 
of 2009. Vaccination in pregnancy boosts the 
concentration of vaccine-specific antibody in 
the mother to increase antibody concentration 
in the infant at birth, providing protection until 
the period of maximum susceptibility or risk 
has passed or until the infant has completed the 
routine infant immunizations.
There are now 3 vaccines, which have 
specific recommendations for routine use in 
pregnancy in an increasing number of coun-
tries, and other vaccines are progressing 
through clinical trials. Here we review the 
mechanisms of protection, the current recom-
mendations and future prospects, and evalua-
tion of safety of vaccines in pregnancy.
MECHANISMS OF PROTECTION 
BY VACCINATION IN PREGNANCY
Immunoglobulin G (IgG) is the only 
antibody isotype actively transferred across the 
placenta from around 13 weeks of gestation 
and increases exponentially during the third tri-
mester such that the concentration of IgG in the 
newborn infant is similar to, or exceeds, that in 
the mother. IgG provides passive immunity to 
the infant in the first months of life.
The neonatal Fc receptor facilitates 
transcytosis of maternal IgG. IgG is trans-
ferred from maternal blood across the syncy-
tiotrophoblast layer of the placenta, initially by 
endocytosis of IgG. Within the acidic endo-
some, IgG binds to membrane-bound neonatal 
Fc receptor, which is then released on the 
fetal side of the syncytiotrophoblast as the pH 
returns to physiologic pH. Neonatal Fc recep-
tor is then recycled back to the maternal side 
of the syncytiotrophoblast to bind further IgG.
There are a number of factors that 
may affect the efficiency of IgG transcytosis, 
including gestation, IgG subclass and mater-
nal infection.1
The concentration of fetal IgG in late 
second and early third trimester is 25%–50% 
lower than that found in term infants, which 
has significant relevance for the timing of 
vaccination in pregnancy to provide protec-
tion to preterm infants. There remains debate 
in the literature about the optimal timing of 
vaccination in pregnancy.2 Vaccination in 
the second trimester would provide longer 
cumulative exposure to maternal IgG, and 
potentially result in higher functional IgG in 
the infant. Later vaccination, around 28–32 
weeks, would more closely match the peak 
of the vaccine response with the timing of 
maximal transplacental transfer of IgG and 
therefore potentially provide greater protec-
tion to the infant. The ideal timing for vacci-
nation is of scientific importance; however a 
more pragmatic approach might be to provide 
a wide window of opportunity for vaccina-
tion in pregnancy, to allow a greater number 
of women the opportunity to be vaccinated.
The 4 subclasses of IgG are trans-
ferred across the placenta with differing 
efficiency—with IgG1 being found in high-
est concentration in cord blood, followed by 
IgG4, IgG3 and IgG2. Therefore, maternal 
immunization with a polysaccharide vaccine, 
inducing predominately IgG2, might offer 
less protection to the infant against infection 
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compared with a protein or protein-conju-
gated vaccine, which elicits predominately 
IgG1 and IgG3.
Maternal infections such as malaria 
and HIV can also affect transplacental trans-
fer of antibody and therefore the concentra-
tion of specific antibody in the infant. This 
underlines the importance of optimizing 
maternal health for the benefit of both mother 
and infant.
While the predominant mechanism of 
protection afforded by maternal vaccination is 
transplacental transfer of IgG, there is poten-
tial for additional protection conferred by 
antibody in breast milk. Secretory IgA (sIgA) 
is thought to protect against diarrheal and res-
piratory pathogens through a variety of mech-
anisms, including immobilization, prevention 
of adhesion or by neutralization of toxins 
or virulence factors.3 Several clinical trials 
have identified significantly higher vaccine-
specific sIgA in the breast milk of women 
vaccinated in the third trimester of pregnancy 
compared with unvaccinated women. These 
antibodies appear long-lived with elevated 
sIgA in breast milk measured up to 7 months 
postpartum. As maternal vaccination strate-
gies develop, it will be important to monitor 
the potential effects of vaccination on the 
composition of breast milk; concerns have 
been raised about the potential blunting of 
infant immune responses to live oral vaccines 
from high breast milk sIgA; however further 
research is required to confirm these findings 
and understand the clinical implications.
VACCINES WITH SPECIFIC 
RECOMMENDATIONS FOR USE IN 
PREGNANCY
Tetanus
Maternal vaccination with inactivated 
tetanus toxoid vaccine has played a major 
role in reducing the global burden of neona-
tal tetanus and has been part of the Expanded 
Programme of Immunization since it began 
in 1974. The World Health Organization esti-
mates that there has been a more than 95% 
reduction in deaths from neonatal tetanus 
since the 1980s, from an estimated 787,000 
deaths in 1988 to 34,019 deaths in 2015 (the 
latest year for which data are available), an 
achievement in which vaccines have played a 
significant role. The vaccine schedule required 
in pregnancy depends on the number of doses 
previously received; a lifetime total of at least 
5 doses are required for maximal protection.4 
The tremendous success of maternal tetanus 
vaccination has set the precedent for further 
development of vaccination in pregnancy.
Influenza
It has been known since the global 
influenza pandemic of 1918 that pregnant 
women are disproportionately affected by 
the complications of influenza. Influenza 
vaccination has been introduced for preg-
nant women in many countries, and the 
World Health Organization recommends that 
pregnant women are the highest priority for 
countries considering the initiation or expan-
sion of seasonal influenza immunization 
programs. Vaccination is offered primarily 
for the protection of the pregnant women, 
but studies have also shown that vaccination 
in pregnancy can protect infants from influ-
enza.5 In countries where recommendations 
for maternal influenza vaccination exist, a 
single dose is recommended at any gestation 
during the influenza season. This should be 
repeated during each pregnancy.
Pertussis
Whole-cell pertussis vaccination in 
pregnancy was first explored in the 1930s, 
but it was not until 2012 that acellular pertus-
sis vaccination first became part of national 
programs for all pregnant women. This was 
introduced first in the United States and 
United Kingdom in response to significantly 
increased rates of pertussis observed across 
all age groups, but particularly in infants less 
than 3 months old, who are at highest risk of 
serious morbidity and mortality. Vaccination 
in pregnancy with a pertussis containing vac-
cine has been shown to be highly effective 
in preventing disease in young infants, with 
vaccine effectiveness of up to 93%.6 Most 
countries recommending its use administer a 
single dose of vaccine in the third trimester; 
however, the United Kingdom has recently 
extended the recommendation to include any 
women from 16 weeks gestation onward. 
As there is currently no monovalent pertus-
sis vaccine available, the pertussis vaccine is 
given in combination with tetanus and diph-
theria, and in some countries also with polio. 
Pertussis vaccination should be repeated in 
each pregnancy.
FUTURE PROSPECTS FOR 
VACCINATION IN PREGNANCY
Group B Streptococcus
Human trials of the group B strepto-
coccus (GBS) vaccines were carried out in the 
1980s, and were based on capsular polysac-
charide (CPS). The initial vaccine was devel-
oped as a plain CPS-based vaccine, but with 
variable immunogenicity in healthy adults, 
subsequent formulations have been devel-
oped as CPS–protein–conjugate vaccines. 
Monovalent, tetanus toxoid–conjugated vac-
cines incorporating each of the 5 major CPSs 
of GBS (Ia, Ib, II, III, V) have been evaluated 
in nonpregnant women in phase 1 and 2 tri-
als. Trivalent vaccines conjugated to CRM
197
 
(nontoxic mutant of diphtheria toxin) have 
entered clinical trials and over 500 pregnant 
women have received the experimental vac-
cine.7 The vaccine appears well tolerated and 
highly immunogenic. A phase 1 clinical trial 
with a GBS protein vaccine (NCT02459262), 
made from the N-terminal domains of the 
Rib and AlphaC surface proteins of GBS, has 
recently been completed.
Respiratory Syncytial Virus
Early clinical trials of a formalin-
inactivated respiratory syncytial virus 
(RSV) infant vaccine resulted in enhanced 
RSV disease in infants, halting further 
development of this vaccine. A number of 
new formulation RSV vaccine candidates 
are in development. These include gene-
based adenovirus vector vaccines, particle-
based vaccines and live attenuated vac-
cines.7 Good safety and immunogenicity of 
an RSV subunit vaccine containing purified 
RSV fusion protein has been demonstrated 
in pregnant women who received the vac-
cine in the third trimester.8 In this study, the 
largest of its kind, both mothers and their 
infants showed a 4-fold rise in serum RSV 
IgG concentration with similar rises in 
breast milk sIgA and IgG. A large, interna-
tional, phase 3 efficacy trial of an RSV F 
nanoprotein vaccine in pregnant women is 
currently in progress (NCT02624947).
Cytomegalovirus
Developing a vaccine to prevent con-
genital cytomegalovirus (CMV) infection is 
complex and our understanding of the immu-
nologic factors that prevent congenital CMV 
transmission is incomplete.9 However, as for 
GBS and RSV there is proof of concept that 
maternal antibody may be protective against 
fetal transmission and severe sequelae from 
disease.
Initial vaccine candidates were live 
attenuated CMV vaccines. Though safe and 
immunogenic in seronegative adults, they 
failed to boost CMV-specific immunity in 
seropositive adults and have failed to prevent 
seronegative women acquiring CMV when 
exposed to young children who were actively 
shedding virus.9 These live attenuated vac-
cines have now been further developed to 
include recombination with less-attenuated 
CMV strains and co-administration with 
interleukin 12. Other vaccines include subu-
nit vaccination incorporating the CMV sur-
face glycoprotein B (gB) that mediates CMV 
cell entry or subunit vaccines using viral vec-
tors. A recombinant protein gB adjuvanted 
with the squalene-based adjuvant MF59 has 
proven safe and immunogenic in phase 1 and 
phase 2 studies in healthy seronegative and 
seropositive adults, transplant recipients and 
adolescents. There have been no trials of any 
CMV vaccine in pregnant women to date.
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SAFETY OF VACCINES IN 
PREGNANCY
The most important consideration 
for pregnant women, health-care provid-
ers, manufacturers and regulators is safety. 
The assessment of this is complicated by the 
frequency of adverse events associated with 
pregnancy itself and, when these occur within 
the context of a clinical trial, it is vital to fully 
assess safety endpoints to make a judgment 
on causality of such events. Knowledge of 
background rates of key adverse events in 
pregnancy and infants is important to assess 
whether events are occurring at a higher fre-
quency than in an unvaccinated population of 
women and their infants.
There is an increasing body of evi-
dence to support the safety of tetanus, influ-
enza and pertussis vaccination in pregnancy 
for the pregnant women, fetus and infant. 
Comparing studies or pooling data is ham-
pered by failure to collect or report essential 
data and by inconsistent use of case defini-
tions. Recently, the Global Alignment of 
Immunization Safety Assessment in Preg-
nancy Project (http://gaia-consortium.net) 
has developed guidelines for the collection of 
essential safety data in clinical trials of vac-
cines in pregnancy and defined key adverse 
obstetric and neonatal events to facilitate 
data harmonization.10 Comparison of stud-
ies and pooling of data are essential to detect 
rare events, which require very large sam-
ple sizes, and thorough safety assessment is 
essential to maintaining confidence in a par-
ticular vaccine and immunization programs.
CONCLUSIONS
The field of maternal vaccination 
is rapidly advancing. There is increasing 
evidence to support the safety, immuno-
genicity and effectiveness of vaccination in 
pregnancy. A number of challenges and key 
knowledge gaps remain including acceptance 
of an increasing number of vaccines with an 
indication for use in pregnancy, optimal tim-
ing of vaccination, the effect of antigen type 
on transplacental transfer of antibody, cor-
relates of protection against key pathogens, 
and the effect on subsequent infant immune 
responses to vaccination.11 Despite these 
challenges, vaccination in pregnancy has and 
continues to play an important role in protect-
ing pregnant women and developing fetuses 
and infants from infection.
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